Desitin launches Biofrontera's Ameluz® in Scandinavia
(Thomson Reuters ONE) -
Biofrontera AG /
Desitin launches Biofrontera's Ameluz® in Scandinavia
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Leverkusen and Hamburg - according to the distribution agreement between the two
companies (see press release of 06-02-2012) Desitin Arzneimittel GmbH has today
started the distribution of Ameluz(®) in Denmark, Norway and Sweden. Pricing was
agreed upon with the respective local agencies prior to the launch. In December
2011 the European Commission had approved Ameluz(®) for marketing and
distribution in the entire EU, Norway, Island and Liechtenstein. Ameluz(®) is
offered as a 2 gram tube, which in photodynamic therapy (PDT) is distributed
onto about 20 cm(2) of affected skin. The launch was prepared by evaluating the
national market environments with leading PDT experts under the dermatologists.
Biofrontera has manufactured Ameluz(®) in packages in the respective local
languages, and Biofrontera's scientists helped to train the Desitin sales force
with respect to the new product.
Dr. Martin Zentgraf, General Manager of Desitin Arzneimittel GmbH: "Ameluz(®) is
one of the most interesting new medicines in dermatology. Its distribution will
considerably enhance our presence in Scandinavia. We are convinced that we will
make Ameluz(®) a great success in these markets."
Comments Prof. Hermann Lübbert, CEO of Biofrontera AG: "The pivotal phase III
trials of Ameluz(®) demonstrated the highest efficacy rates known to us from any
controlled phase III with a drug against actinic keratosis. Even the Product
Information that was approved by the European Commission cites the superiority
of Ameluz(®) towards its direct competitor and provides detailed numbers to
substantiate this. Actinic keratoses are more frequently treated with
photodynamic therapy in the highly developed health care systems of Scandinavia
than in Germany. Therefore, these countries constitute an important and seminal
market for Ameluz(®)."
Background
Ameluz(®) (developed as BF-200 ALA gel) was centrally approved in the entire
European Economic Area for the treatment of actinic keratosis in December 2011.
The product is applied in the relatively novel photodynamic therapy (PDT). PDT
of actinic keratosis lesions with Ameluz(®) leads to very high efficacy and
excellent cosmetic results, without the side-effects and discomfort of a long-
term treatment. The treatment can be repeated after three months if residual
lesions remain. A direct clinical comparator study testing the clearance of all
actinic keratoses of a patient proved the strong superiority of Ameluz(®)
compared to its closest competitor.
Actinic keratosis is a superficial skin cancer that is still restricted to the
upper skin layer (the epidermis). These tumours result from UV-light induced
damage accumulating during the entire life time. Thus, they occur very
frequently in sun-exposed skin regions. In about 10-15% of the affected people
the actinic keratosis lesions develop into malignant, potentially fatal squamous
cell carcinomas.
About Biofrontera AG
Biofrontera Pharma GmbH is a wholly-owned subsidiary of Biofrontera AG. The
Biofrontera group aims at attending and treating the skin, recognizing the
aesthetic needs of a person's visual reflection. Biofrontera is listed at the
regulated market of the Frankfurt stock exchange under the symbol B8F and the
ISIN number DE0006046113.
www.biofrontera.com
This press release contains forward-looking statements based on the currently
held beliefs and assumptions of the management of Biofrontera AG, which are
expressed in good faith and, in their opinion, reasonable. Forward-looking
statements involve known and unknown risks, uncertainties and other factors,
which may cause the assumptions expressed or implied in this press release to be
faulty. Given these risks, uncertainties and other factors, recipients of this
document are cautioned not to place undue reliance on the forward-looking
statements. Biofrontera AG disclaims any obligation to update these forward-
looking statements to reflect future events or developments.
For further information please contact:
Werner Pehlemann
CFO
+ 49 214 87632 0
+ 49 214 87632 90
w.pehlemann(at)biofrontera.com
Biofrontera AG
Hemmelrather Weg 201
D- 51377 Leverkusen, Germany
Martin Zentgraf, MD
General Manager
Tel. +49 40-59101-0
Fax +49 40 59101-366
zentgraf(at)desitin.de
Desitin Arzneimittel GmbH
Weg beim Jäger 214
D-22335 Hamburg
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Biofrontera AG via Thomson Reuters ONE
[HUG#1638244]
Unternehmensinformation / Kurzprofil:
Datum: 03.09.2012 - 09:58 Uhr
Sprache: Deutsch
News-ID 179659
Anzahl Zeichen: 5618
contact information:
Town:
Leverkusen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 163 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Desitin launches Biofrontera's Ameluz® in Scandinavia"
steht unter der journalistisch-redaktionellen Verantwortung von
Biofrontera AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
